Latest Content

Chemo-free zanubrutinib plus rituximab in phase 3 MANGROVE cuts progression/death risk 43% vs BR for frontline mantle cell lymphoma.

New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.

Reconstructed Kaplan-Meier data benchmark durability of CAR T-cell therapy, bispecific antibodies, and zanubrutinib combos for relapsed follicular lymphoma.

The House passed HR 5347 to extend flexible Medicare ACO quality reporting and support smaller practices transitioning to digital measures.

Topical delgocitinib in chronic hand eczema improves clearance and itch fast, with placebo-like safety.

New wastewater data and prior research suggest COVID-19 may follow recurring spring and summer transmission patterns, unlike influenza and RSV.

Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.

Longer sleep is linked to lower glycemic variability and reduced deviation risk in adolescents; higher daytime variability predicted shorter subsequent sleep.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.